Category Specific RSS

alzheimers

Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank

Shares in drug development company Actinogen Medical (ASX: ACW) have plummeted following the results release of their Phase 2a clinical…

2 years ago

Cogstate buys back exclusive rights to its brain health testing tech from Eisai

Neuroscience tech company Cogstate (ASX: CGS) has re-acquired the global rights to its technology previously exclusively licensed to Japanese pharma…

2 years ago

New trial results from Actinogen hold promise for Alzheimer’s treatment

Most people experience some level of cognitive decline as they get older. It’s a cruel, albeit normal part of the…

4 years ago

Better than a sudoku: could this drug be the key to preventing Alzheimer’s?

Our minds can be our greatest asset and our biggest enemy. The same humans that built aeroplanes, rockets and the…

5 years ago